FMC (FMC) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue rose 9% year-over-year to $1,065 million, driven by strong volume growth in North and Latin America, new product launches, and improved market conditions, despite pricing pressure and cost headwinds.

• GAAP net income reached $66 million, reversing a prior year loss, with adjusted EBITDA up 15% to $201 million and adjusted EPS up 57% to $0.69.

• Project Focus restructuring expanded, targeting $125–$150 million in 2024 cost savings and over $225 million annual run-rate savings by end of 2025.

• New product launches, especially fluindapyr and Isoflex-based products, were key growth drivers, with strong demand for fungicides and diamides.

• Restructuring and cost savings largely offset cost of goods sold headwinds, supporting profitability.

Financial highlights

• Adjusted EBITDA for Q3 was $201 million (+15% YoY), with margin improving to 18.9%; adjusted EPS was $0.69 (+57% YoY).

• Free cash flow for Q3 was $132 million, up $100 million year-over-year; year-to-date free cash flow reached $225 million, up over $1 billion.

• Gross margin for Q3 was $386.4 million (36% of revenue), down from 39% YoY.

• Gross debt at quarter end was $4.07 billion, net debt $3.7 billion, and net debt/EBITDA at 4.5x.

• ROIC (non-GAAP) for the trailing twelve months was 6.85%.

Outlook and guidance

• Full-year 2024 revenue expected at $4.33–$4.44 billion, down 2% at midpoint; adjusted EBITDA at $885–$915 million (–8% YoY); adjusted EPS at $3.16–$3.52 (–12% YoY).

• Free cash flow for 2024 guided at $400–$500 million.

• Q4 2024 revenue expected at $1.30–$1.41 billion, up 19% at midpoint, with adjusted EBITDA of $321–$351 million and adjusted EPS of $1.47–$1.83.

• 2025 outlook includes ~6% revenue growth (mainly volume), cost savings at the higher end of $150–$200 million, and pricing assumptions remain uncertain.

• Project Focus expected to deliver over $225 million in annual run-rate savings by end of 2025.